NCT07215130 Selective Removal of Endometriotic Lesions Using CUSA Clarity in Ovarian Endometriomas
| NCT ID | NCT07215130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kanazawa University |
| Condition | Ovarian Endometrioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-01-30 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2025-01-30 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the feasibility and tissue selectivity of a novel surgical technology, the Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity, in the management of ovarian endometriomas. Ovarian endometriomas are cysts caused by endometriosis that can damage ovarian reserve when treated by conventional surgery. In this study, ovarian cyst wall specimens are examined ex vivo using different Tissue Select settings of the CUSA device. Histopathological analyses are performed to determine whether endometriotic epithelium can be selectively removed while preserving normal ovarian tissue. The findings may contribute to developing fertility-preserving surgical approaches for women with endometriomas.
Eligibility Criteria
Inclusion Criteria: * Female patients diagnosed with ovarian endometrioma who undergo surgical treatment (cystectomy or adnexectomy) at Kanazawa University Hospital between January 1, 2025, and March 31, 2027. * Written informed consent obtained prior to study participation. * Age ≥ 20 years at the time of consent. * For patients with previously stored endometrioma specimens under a broad consent, additional written consent for participation in this study will be obtained. Exclusion Criteria: * Patients with suspected malignancy based on preoperative imaging. * Patients judged by the attending physician to be unsuitable for participation in this study for any reason.
Contact & Investigator
Kaoru Abiko, MD, PhD
PRINCIPAL INVESTIGATOR
Kanazawa University, Department of Obstetrics and Gynecology
Frequently Asked Questions
Who can join the NCT07215130 clinical trial?
This trial is open to female participants only, aged 20 Years or older, studying Ovarian Endometrioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07215130 currently recruiting?
Yes, NCT07215130 is actively recruiting participants. Contact the research team at tkanda@staff.kanazawa-u.ac.jp for enrollment information.
Where is the NCT07215130 trial being conducted?
This trial is being conducted at Kanazawa, Japan.
Who is sponsoring the NCT07215130 clinical trial?
NCT07215130 is sponsored by Kanazawa University. The principal investigator is Kaoru Abiko, MD, PhD at Kanazawa University, Department of Obstetrics and Gynecology. The trial plans to enroll 10 participants.